How do you approach a patient with metastatic inflammatory TNBC at diagnosis with a good PS?
PDL1 status pending; BRCA wild type
Answer from: Medical Oncologist at Academic Institution
I would approach this patient with weekly nab-paclitaxel and atezolizumab if she was PDL-1 positive (just like the Impassion Trial, NEJM 2018:379;2018-21). If the tumor (actually the stroma) was PD-L1 negative, then I would treat with paclitaxel and carboplatin (80 mg/m2 and AUC 2 days 1, 8, and 15 ...